Date: 2016-02-25
Type of information: Collaboration agreement
Compound: allogeneic chimeric antigen receptor (CAR) T cell therapies for up to six targets
Company: Baxalta (USA - IL) Precision BioSciences (USA - NC)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: immunotherapy product/cell therapy/gene therapy. CAR T cell therapy technologies isolate cells from cancer patients’ blood and re-engineer them to specifically target receptors on tumor cells. The reprogrammed cells are multiplied in a laboratory and then returned to the patient to target the tumor.
Disease:
Details: * On February 25, 2016, Baxalta and Precision BioSciences announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. Precision BioSciences’ proprietary ARCUS genome editing technology enables the production of CAR T cells derived from healthy donors rather than relying on the patient. This approach aims to overcome the manufacturing-related limitations with existing CAR T therapies and enable a broader range of malignancies to be targeted. Precision BioSciences will be responsible for performing early-stage research activities up to Phase 2, following which Baxalta has the exclusive right to opt in for late-stage development and commercialization.
Under the terms of the agreement, Baxalta and Precision BioSciences will develop CAR T therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017.
Financial terms: Precision BioSciences will receive an upfront payment of $105 million from Baxalta , with additional option fees, developmental, clinical, regulatory, and sales milestones, potentially totaling up to $1.6 billion , in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States . Additional terms and initial targets were not disclosed.
Latest news:
